Blueprint Medicines Corp

NASDAQ:BPMC  
86.82
+2.71 (+3.22%)
Products, Regulatory

Blueprint Medicines Presents Arrow Trial Data For Gavreto Highlighting Durable Clinical Activity In Patients With Metastatic Ret Fusion-Positive Non-Small Cell Lung Cancer

Published: 05/19/2021 21:23 GMT
Blueprint Medicines Corp (BPMC) - Blueprint Medicines Presents Arrow Trial Data for Gavreto® (pralsetinib) Highlighting Durable Clinical Activity in Patients With Metastatic Ret Fusion-positive Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Blueprint Medicines-88% Orr & Median Duration of Response Not Reached in Treatment-naÏve Patients With Nsclc Enrolled After Expansion of Trial Criteria.
Blueprint Medicines - 53% Orr in Heavily Pre-treated Patients With Ret Fusion-positive Tumors Beyond Non-small Cell Lung Cancer and Thyroid Cancer.
Blueprint Medicines Corp - Across Tumor Types, Gavreto Was Well-tolerated With No New Safety Signals Observed.